MedPath

Gestational Diabetes Diagnostic Methods

Not Applicable
Completed
Conditions
Gestational Diabetes
Interventions
Behavioral: Dietary modification and medications
Registration Number
NCT01540396
Lead Sponsor
University of Pittsburgh
Brief Summary

This is a pilot feasibility study of 40 pregnant women to test the investigators' recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. The two methods that are being compared are the 2 hour 75 gram OGGT (2011 ADA guidelines) versus a 1 hour 50 gram GCT + 3 hour 100 gram OGTT if the 1 hour result is abnormal (Carpenter and Coustan criteria).

Detailed Description

This is a pilot feasibility study of 40 pregnant women between 24-28 weeks gestation to test the investigators recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes.

Forty women 18 years of age or older will be recruited at 20-24 weeks pregnancy from the ob/gyn outpatient practices at Magee-Women's hospital (MWH). Eligible women will return to MWH main lab between 24-28 weeks gestation for the routine 1 hour 50gm glucose challenge test. Women with blood glucose values less than 200 will be randomized to receive either the fasting 2 hour 75 gm oral glucose tolerance test (OGTT)or the 3 hour 100 gm OGGT within two weeks. Gestational diabetes will be determined for the 2 hour 75 gm OGGT arm based on the 2011 ADA guidelines and the 3 hour 100 gm OGGT arm based on the Carpenter and Coustan criteria. Patients and their providers will be informed of the diagnosis of gestational diabetes, but they will be blinded to the criteria used to make the diagnosis as well as the specific results of glucose tolerance testing.

Chart reviews will be conducted to assess for perinatal maternal and infant health factors (e.g.pregnancy weight, gestational weight gain, co morbidities) as well as for data on perinatal outcomes related to GDM such as macrosomia, c-sections, and birth trauma. Two brief self-administered questionnaire will assess participants' views on screening for gestational diabetes and assess participants experience with and solicit feedback on the study procedures.

At the end of this pilot study, the investigators will have experience with recruitment, retention, and randomization procedures and have made the necessary protocol revisions. If successful, this feasibility study will provide the preliminary data and feasibility justification needed to conduct a larger randomized control trial to compare the effectiveness of two diagnostic methods for gestational diabetes.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
47
Inclusion Criteria
  • Singleton pregnancy
  • Plan to undergo gestational diabetes screening at 24-28 weeks' gestation.
Read More
Exclusion Criteria
  • Existing Type 1 or Type 2 diabetes
  • Diabetes diagnosed early in pregnancy (less than 24 weeks gestation)
  • Multiple gestation (e.g. twins, triplets)
  • Chronic hypertension (requiring medications)
  • Oral, IM or IV corticosteroid use within the previous 30 days
  • Major congenital anomaly or anticipated preterm delivery before 28 weeks
  • Inability to complete 50 gram GCT before 28 completed weeks' gestation
  • Patients with known HIV, Hepatitis B or C virus.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
100 gram OGTTDietary modification and medicationsA 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
75 Gram OGTTDietary modification and medicationsThe 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
Primary Outcome Measures
NameTimeMethod
Cesarean deliveryWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

Primary or repeat cesarean delivery

MacrosomiaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

Defined as birthweight \>90th percentile for gestational age or birthweight \>4000 grams

Diagnosis of gestational diabetesWill be followed from study enrollment until delivery (approximately 40 weeks' gestation)

Assess how frequently a diagnosis of gestational diabetes is made

Secondary Outcome Measures
NameTimeMethod
Neonatal hyperbilirubinemiaFirst 7 days of life

Defined as bilirubin greater than 5 mg/dL over 24 hours from heel stick

Infant birth traumaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

Defined as shoulder dystocia/brachial plexus injuries

Maternal birth traumaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

3rd or 4th degree perineal laceration or postpartum hemorrhage

Neonatal hypoglycemiaFirst 24 hours of life

Defined as blood glucose less than 80 mg/dL from heel stick within 1 hour after delivery

Pre-eclampsia or gestational hypertensionWill be assessed from study enrollment until 30 days after delivery

New onset hypertension +/- proteinuria

Trial Locations

Locations (1)

Magee-Womens Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath